Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline

Core Viewpoint - BioMarin Pharmaceutical (BMRN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][3]. Financial Expectations - The consensus estimate for BioMarin's quarterly earnings is $0.25 per share, reflecting a year-over-year decrease of 72.8%. Revenues are projected to be $829.66 million, representing an 11% increase from the same quarter last year [3]. - Over the last 30 days, the consensus EPS estimate has been revised down by 1.16%, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model indicates that the Most Accurate Estimate for BioMarin is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [12]. - BioMarin currently holds a Zacks Rank of 3 (Hold), making it challenging to predict a positive earnings surprise [12]. Historical Performance - In the last reported quarter, BioMarin was expected to incur a loss of $0.15 per share but instead reported earnings of $0.12, achieving a surprise of +180.00%. The company has beaten consensus EPS estimates in each of the last four quarters [13][14]. Market Context - The performance of BioMarin's stock may not solely depend on earnings results, as other factors can influence stock movement. Stocks can decline despite an earnings beat or rise despite a miss due to unforeseen catalysts [15][17].